Search Medical Condition
Please enter condition
Please choose location from dropdown

Chia-Yi, Taiwan Clinical Trials

A listing of Chia-Yi, Taiwan clinical trials actively recruiting patients volunteers.

RESULTS

Found (38) clinical trials

Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection

First line therapy: open labeled, randomized control trial, randomized into one of the three groups Group (A): triple therapy for 14 days D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid Group (B): non-bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin ...

Phase

0.0 miles

Learn More »

Imputation of PaO2 From SaO2

The Sequential Organ Failure Assessment (SOFA) score is validated as a measure of severity of illness over time in intensive care unit (ICU) patients and can be used to follow the course of organ dysfunction and response to treatment1. SOFA has become a frequently used scoring system of patients in ...

Phase N/A

0.0 miles

Learn More »

Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy

This is a multi-center, open-label, Simon's 2-stage, phase II study of paclitaxel and cisplatin as neoadjuvant therapy in patients with FIGO IB2 or IIA2, squamous cell cervical carcinoma of the uterine cervix. Primary Objectives: Overall survival Secondary Objectives: Safety Progression-free survival Response rate Postoperative RT/CRT rate To assess Quality-of-life An ...

Phase

0.0 miles

Learn More »

Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer

This study is designed to determine the feasibility of administering adjuvant carboplatin, paclitaxel, and bevacizumab without unacceptable significant AE in patients with epithelial ovarian cancer after neoadjuvant carboplatin/cisplatin, and paclitaxel and interval cytoreductive surgery, primary peritoneal cancer or fallopian tube cancer. This study will also investigate progression free and to ...

Phase

0.0 miles

Learn More »

the Peer-Led Self-Management Program

Most current self-management programs are developed for implementation by healthcare professionals. These professionals cannot fully perceive disease management needs and obstacles of older adults due to a lack of similar illness experience. To develop a self-management training program for older adult peer leaders with diabetes and to assess its feasibility. ...

Phase N/A

0.0 miles

Learn More »

Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients

The purpose of this study is to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.

Phase

0.0 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to assess ...

Phase

0.0 miles

Learn More »

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

Acute intracerebral haemorrhage (ICH) is the most serious and least treatable form of stroke, accounting for at least 10% of the 20 million new strokes that occur globally each year. Survivors of ICH are at high risk of recurrent ICH and other serious cardiovascular events. While there is strong evidence ...

Phase

0.0 miles

Learn More »

Liver Test Study of Using JKB-122 in HCV-Positive Patients

The primary objective of this study is to assess changes in alanine aminotransferase (ALT) in hepatitis C virus (HCV)-infected subjects given daily doses of JKB-122 for 3 months who have been nonresponsive to, intolerable to, or relapsed from prior interferon-based therapies (pegylated or standard) either alone or in combination with ...

Phase

0.0 miles

Learn More »

Mucopolysaccharidosis I (MPS I) Registry

The MPS I Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact: In Asia-Pacific - Vivian Liu, +65-6431-2548, Vivian.liu@genzyme.com In Europe - +31-35-699-1232, europe@mpsiregistry.com In Latin America - +617-591-5500, help@mpsiregistry.com In North America - +617-591-5500, help@mpsiregistry.com

Phase N/A

0.0 miles

Learn More »